Best Neurology Companies in Illinois, United States
The 34 best Neurology companies in Illinois, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Assertio.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Illinois
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Assertio Developer of drugs to treat pain and other neurological diseases | $906M | 139 mo ago | Acquired | — | 29 29 → 65 (+124%) | — | — |
| 2 | Emalex Biosciences Developer of therapeutics for the treatment of rare and orphan neurological conditions | $285M | 47 mo ago | Acquired | Jeffrey Aronin Founder | 19 | 52 patents Formulation and delivery of ecopipam for Tourette syndrome treatment | — |
| 3 | Naurex Clinical-stage company developing novel therapies for depression and other CNS disorders. | $162M | 130 mo ago | Acquired | Joseph Moskal Founder | 56 | 183 patents Synthesis of diazaspiro lactam heterocycles and related peptide/NMDA modulators for CNS therapeutics | — |
| 4 | Jaguar Gene Therapy Developer of gene therapies using adeno-associated virus technology | $139M | 55 mo ago | Series B | Joe Nolan Chief Executive Officer | 67 | — | — |
| 5 | Aptinyx Developer of small molecules that modulate the NMDA receptor for the treatment of CNS diseases | $135M | 61 mo ago | Series B | Norbert Riedel Executive Chairman | 37 | 278 patents Novel spiro-lactam compounds modulating NMDA receptors for neurotherapeutics | — |
| 6 | Vanqua Bio Developer of therapeutics to treat neurodegenerative diseases | $130M | 32 mo ago | Series B | Jim Sullivan Co-Founder and CEO | 29 | — | — |
| 7 | Rhaeos Developer of a noninvasive device to monitor CSF and manage hydrocephalus 35Talent top 28%Funding top 32%Patents top 32%Innovation top 34% All 9 signals ▾Talenttop 28% Fundingtop 32% Patentstop 32% Innovationtop 34% Moattop 38% Globalbottom 40% Marketbottom 24% Techbottom 23% Newsbottom 18% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $12.8M across 13 rounds · 13 rounds over 6 yrs (2.2/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $13M | 18 mo ago | Series A | Amit Ayer Co-Founder | 10 10 → 20 (+100%) | 16 patents Medical wearable temperature monitoring and fluid flow sensing technologies | — |
| 8 | Amphix Bio Developer of supramolecular therapeutic peptides for regenerative medicine applications | $13M | 10 mo ago | Seed | Samuel Stupp Co-Founder | 2 | — | — |
| 9 | Madison Scientific Developer of an integrated management solution for hydrocephalus treatment optimization | $11M | 21 mo ago | Series A | Tyler Wanke Co-Founder & CEO | — | — | — |
| 10 | Savant HWP Developer of anti-addiction therapies | $7M | 145 mo ago | Deadpooled | Terence Boardma Co-Founder & VP | — | — | — |
| 11 | Wesana Health Developer of therapeutic solutions for the treatment of multiple neurological disorders | $4M | 67 mo ago | Public | Daniel Carcillo Founder & CEO | 33 | — | — |
| 12 | Belay Diagnostics Developer of sequencing technologies to detect brain and spinal cord cancers | $3M | 17 mo ago | Funding Raised | Jonathan Dudley Co-Founder | — | — | — |
| 13 | Dystrogen Therapeutics Developing chimeric cell therapies for muscle wasting disorders like Duchenne Muscular Dystrophy | $1M | 86 mo ago | Seed | Kris Siemionow Co-Founder & CEO | 5 | — | — |
| 14 | VasSol 3D blood flow analytics software for cerebrovascular diagnosis and treatment | $928K | 187 mo ago | Early Stage | Chuck Doherty CEO | 11 | 22 patents Advanced phase-contrast MRI techniques for cardiovascular blood‑flow quantification and motion correction | — |
| 15 | Abiant Imaging tools for diagnosis of neurodegenerative diseases | $600K | 205 mo ago | Deadpooled | Dawn Matthews President and CEO | — | — | — |
| 16 | Neurodon Targeting cellular stress to revolutionize medicine with disease-modifying therapeutics | $500K | 41 mo ago | Seed | — | 2 | 23 patents SERCA-modulating quinoline therapeutics for diabetes and related metabolic diseases | — |
| 17 | ENCUE Developer of orally deliverable, synthetic receptor modulators for neurological disorders | $500K | 25 mo ago | Funding Raised | Alicia Loffler Co-Founder & CEO | — | — | — |
| 18 | Winston Pharmaceuticals Small Molecule Drugs for Pain | $375K | 174 mo ago | Public | Joel Bernstein Founder & CEO | 9 | — | — |
| 19 | Great Lakes Neuroscience Develops therapeutics for neuro-degenerative diseases as a tech prospector and translator | $310K | 116 mo ago | Deadpooled | Siddhartha Pidhadia Co-Founder | 7 | — | — |
| 20 | Nerve Access Special formulation of insulin to treat Alzheimer's disease. | $245K | 142 mo ago | Funding Raised | Yaser Maksoud President and Founder | — | — | — |
| 21 | NeuroLucent Developer of therapeutic agents to treat Alzheimer's-related memory loss | $203K | 101 mo ago | Deadpooled | Glenn Gottfried Co-Founder & Chairman | — | — | — |
Top 12 Neurology companies in Illinois
#1
Seed · Chicago, Illinois · founded 2019 · 2 employees$12.8Mraised▾
Developer of supramolecular therapeutic peptides for regenerative medicine applications. It focuses on creating regenerative therapeutics using supramolecular chemistry to promote healing after traumatic injury and improve human healthspan. The company's platform utilizes supramolecular structures to encode interactions between molecules, activate regenerative signals, and create scaffolds for tissue growth. This technology aims to regenerate cells and tissues effectively without the challenges associated with cell therapies. The company has pipeline programs in neurological and musculoskeletal regeneration.
- Dec 2025Seed$12.5M
- Sep 2024Grant (prize money)—
- Mar 2022Grant (prize money)$252.9K
#2
Series A · Evanston, Illinois · founded 2018 · 10 employees$12.8Mraised▾
Developer of a noninvasive device to monitor CSF and manage hydrocephalus. It offers a wireless non-invasive thermal flow sensor that is placed over the neck to monitor the ventricular shunt function and detect or measure CSF. Its data is transferred to an app to manage hydrocephalus.
- Apr 2025Grant (prize money)$298.8K
- Apr 2025Grant (prize money)$4.1M
- Mar 2025Grant (prize money)$1.9M
- Mar 2025Grant (prize money)$306.5K
#3
Series A · Chicago, Illinois · founded 2020$11Mraised▾
Developer of an integrated management solution for hydrocephalus treatment optimization. The company focuses on creating tools and resources to improve patient care. It aims to provide a comprehensive approach to address the complexities of hydrocephalus management. The goal is to support healthcare professionals in delivering effective treatment strategies.
- Jan 2025Series A$10M
- Sep 2023Grant (prize money)$698.7K
- Dec 2020Grant (prize money)$256K
#4
Funding Raised · Chicago, Illinois · founded 2022$2.6Mraised▾
Developer of sequencing technologies to detect brain and spinal cord cancers. It offers Belay Summit that detects mutations and aneuploidy in CSF for diagnosis and management of primary and secondary CNS malignancies and Belay Vantage uses quantitative polymerase chain reaction to evaluate MGMT promoter methylation in cerebrospinal fluid forcentral nervous system tumors.
- May 2025Grant (prize money)$1.1M
- Apr 2025Grant (prize money)$1.1M
- Jul 2024Grant (prize money)$303.8K
#5
Series B · Chicago, Illinois · founded 2019 · 29 employees$130Mraised▾
Developer of therapeutics to treat neurodegenerative diseases. Ithas developed targeted therapies by using patient iPSC-derived neuronal cells. The lead program is GCASE that targets the genetic association between the GBA1 gene, to stop the progression of Parkinson's disease, Gaucher, ALS, Alzheimer's, and related neurological diseases.
- Feb 2024Series B$45M
- Sep 2021Series B$85M
#6
Acquired · Northbrook, Illinois · founded 2018 · 19 employees$285Mraised▾
Developer of therapeutics for the treatment of rare and orphan neurological conditions. The company has developed a compound known as Ecopipam used for the treatment of pediatric Tourette Syndrome. It is a potent and selective antagonist of the human D1 receptor family.
- Nov 2022Series D$250M
- Mar 2021Series C$35M
- Jun 2020Venture Debt$15M
#7
Acquired · Lake Forest, Illinois · founded 1995 · 29 employees$906.3Mraised▾
Developer of drugs to treat pain and other neurological diseases. It offers Nucynta ER indicated for the management of pain associated with diabetic peripheral neuropathy (DPN), Gralise for the management of postherpetic neuralgia (PHN), Cambia for acute treatment of migraine attacks, Lazanda for the management of breakthrough pain in cancer patients; and Zipsor, liquid filled capsules for relief of mild to moderate acute pain. Its pipeline developing drugs include cebranopadol, analgesic for the treatment of moderate to severe chronic nociceptive and neuropathic pain.
- Mar 2015Conventional Debt$575M
- Sep 2014Post IPO$300M
- Jun 2008Conventional Debt$3.8M
- Apr 2003Post IPO$20M
#8
Series B · Evanston, Illinois · founded 2015 · 37 employees$135Mraised▾
Developer of small molecules that modulate the NMDA receptor for the treatment of CNS diseases. The company has a platform for discovering compounds that work through a novel mechanism -modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.
- Sep 2021Conventional Debt$50M
- Dec 2017Series B$70M
- Sep 2016Grant (prize money)$2.2M
- May 2016Grant (prize money)$311.9K
#9
Series B · Lake Forest, Illinois · founded 2019 · 67 employees$139Mraised▾
Developer of gene therapies using adeno-associated virus technology. The company has AAV9 vector-based gene therapies which include JAG101 V for galactosemia, JAG201 for autism spectrum disorder, JAG301 for Type 1 diabetes, AXV101 for BBS1, a neurometabolic condition.
- Mar 2022Series B—
- Apr 2021Series B$139M
#10
Acquired · Evanston, Illinois · founded 2008 · 56 employees$162.1Mraised▾
Naurex is a clinical-stage company developing novel therapies for depression and other CNS disorders. The company lead product candidate, Rapastinel, is in late-stage clinical development as an adjunctive therapy for patients with major depressive disorder. The company's second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder.
- Dec 2015Series C$80M
- May 2014Series B$25M
- Dec 2012Series B$38M
- May 2011Series A$18M
#11
Funding Raised · Evanston, Illinois · founded 2023$500Kraised▾
Developer of orally deliverable, synthetic receptor modulators for neurological disorders. It focuses on creating therapeutics to address cognitive dysfunction associated with neurological diseases. The approach enhances synaptic function and neuroplasticity related to learning and memory. The therapeutics aim to improve the quality of life for patients and their families by restoring synaptic plasticity. The proprietary platform technology develops novel receptor modulators that are fully synthetic and tractable.
- Sep 2024Grant (prize money)$500K
#12
Seed · Chicago, Illinois · founded 2012 · 2 employees$500Kraised▾
Targeting cellular stress to revolutionize medicine with disease-modifying therapeutics. This is a biotechnology company focused on creating innovative treatments by addressing cellular stress at its source. The company targets calcium imbalance, a key factor in diseases like diabetes, Alzheimer’s, Parkinson’s, and Duchenne muscular dystrophy. Their research centers on regulating cellular calcium transport to relieve stress pathways and promote cellular health. They develop proprietary small molecules that modulate the SERCA enzyme, accelerating calcium transport and relieving endoplasmic reticulum stress. This approach aims to provide disease-modifying effects, potentially changing patients’ lives. The company's focus is on preclinical development, research, and partnerships to advance their therapeutics. The company is involved in drug discovery, pharmaceutical research, and biotech innovation.
- May 2023Grant (prize money)$286.3K
- Aug 2020Grant (prize money)$2M
- Aug 2020Grant (prize money)$2M
- Oct 2019Seed$500K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neurotech in Illinois is moving
A read on the academic research around Neurotech in Illinois — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 95 papers.
- University of Illinois Chicago51
- University of Illinois Urbana-Champaign12
- Illinois Institute of Technology12
- Southern Illinois University School of Medicine9
- Illinois College7
- Deep brain stimulation6
- Neuroscience6
- Essential tremor5
- Stimulation2
- Microelectrode2
- Deep brain stimulation20
- Neuroscience20
- Stimulation19
- Neurostimulation11
- Essential tremor8
- Deep brain stimulation1→3
- Parkinson's disease1→3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.